KeyCorp Cuts Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target to $10.00

Recursion Pharmaceuticals (NASDAQ:RXRX) had its target price lowered by KeyCorp from $12.00 to $10.00 in a research note published on Wednesday,Benzinga reports. KeyCorp currently has an overweight rating on the stock.

Separately, Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $8.75.

Recursion Pharmaceuticals Trading Down 5.2 %

Shares of Recursion Pharmaceuticals stock opened at $6.88 on Wednesday. The firm’s 50 day simple moving average is $6.94 and its two-hundred day simple moving average is $7.01. The firm has a market capitalization of $2.69 billion, a price-to-earnings ratio of -4.50 and a beta of 0.85. Recursion Pharmaceuticals has a 12-month low of $5.60 and a 12-month high of $15.74. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. During the same period in the previous year, the company earned ($0.43) earnings per share. Recursion Pharmaceuticals’s revenue was up 147.6% on a year-over-year basis. Analysts predict that Recursion Pharmaceuticals will post -1.57 EPS for the current year.

Insider Buying and Selling at Recursion Pharmaceuticals

In related news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $6.67, for a total transaction of $76,351.49. Following the sale, the director now directly owns 7,089,007 shares of the company’s stock, valued at $47,283,676.69. This trade represents a 0.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now directly owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. The trade was a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 55,341 shares of company stock worth $393,490. Insiders own 15.75% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RXRX. Allspring Global Investments Holdings LLC purchased a new stake in shares of Recursion Pharmaceuticals during the 3rd quarter worth about $25,000. GAMMA Investing LLC raised its holdings in Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after purchasing an additional 4,948 shares during the period. Farther Finance Advisors LLC boosted its position in Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after purchasing an additional 4,091 shares in the last quarter. KBC Group NV grew its holdings in Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after purchasing an additional 3,377 shares during the period. Finally, Amalgamated Bank increased its position in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after buying an additional 2,459 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.